Barchart on MSN
Is Wall Street bullish or bearish on Amgen stock?
Amgen Inc. (AMGN), headquartered in Thousand Oaks, California, discovers, develops, manufactures, and delivers human ...
Freedom Broker analyst Ilya Zubkov downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and raises the price target from $450 to $470. Leerink Partners analyst David Risinger maintains Amgen (NASDAQ:AMGN) ...
Amgen reported strong Q3 2026 results, with revenue of US$10.37b, GAAP net income of US$3.86b, and raised full year guidance ...
Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key ...
Amgen has climbed to a recent close of US$407.44 after a strong multi year run, which puts fresh focus on whether that price ...
Amgen Inc. is upgraded to a cautious Buy, reflecting improved fundamentals, a diversified pipeline, and a decent risk/reward profile despite recent underperformance versus the S&P. Key growth drivers ...
Amgen delivers consistent, market-beating returns, supported by a robust growth portfolio and prudent capital allocation. AMGN’s pipeline strength is evident, with 16 drugs on track for blockbuster ...
Amgen (NASDAQ:AMGN) and AstraZeneca reported Phase 3 results this week for Tezspire in eosinophilic esophagitis, a condition that makes swallowing difficult. The trial met both of its main goals, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results